iCAD (NASDAQ:ICAD) Cut to Sell at StockNews.com

StockNews.com cut shares of iCAD (NASDAQ:ICAD) from a hold rating to a sell rating in a research report report published on Wednesday morning.

iCAD Trading Down 8.0 %

NASDAQ:ICAD opened at $3.32 on Wednesday. The firm has a market capitalization of $88.11 million, a price-to-earnings ratio of -25.54 and a beta of 1.47. The firm’s fifty day simple moving average is $2.34 and its 200 day simple moving average is $1.87. iCAD has a twelve month low of $1.18 and a twelve month high of $3.78.

Hedge Funds Weigh In On iCAD

Hedge funds and other institutional investors have recently made changes to their positions in the business. Summit Trail Advisors LLC acquired a new position in shares of iCAD during the 4th quarter valued at $214,000. waypoint wealth counsel lifted its holdings in iCAD by 44.0% in the 4th quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock worth $26,000 after buying an additional 4,400 shares in the last quarter. Essex LLC acquired a new position in iCAD in the 3rd quarter worth $216,000. Wells Fargo & Company MN lifted its holdings in iCAD by 51.3% in the 4th quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company’s stock worth $72,000 after buying an additional 13,402 shares in the last quarter. Finally, Integrated Wealth Concepts LLC acquired a new position in iCAD in the 4th quarter worth $92,000. Institutional investors and hedge funds own 24.61% of the company’s stock.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.